Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Umbreen Hafeez, Adam C Parslow, Hui K Gan & Andrew M Scott. (2020) New insights into ErbB3 function and therapeutic targeting in cancer. Expert Review of Anticancer Therapy 20:12, pages 1057-1074.
Read now
Read now
Wei Zhan, Xin Liao, Lianghe Li, Zhongsheng Chen, Tian Tian, Lei Yu & Zupeng Chen. (2019) In vitro mitochondrial-targeted antioxidant peptide induces apoptosis in cancer cells. OncoTargets and Therapy 12, pages 7297-7306.
Read now
Read now
Laurence Booth, Jane L. Roberts, Francesca Avogadri-Connors, Richard E. Cutler$suffix/text()$suffix/text(), Alshad S. Lalani, Andrew Poklepovic & Paul Dent. (2018) The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biology & Therapy 19:3, pages 239-247.
Read now
Read now
Lisa C. Schmitt, Alexander Rau, Oliver Seifert, Jonas Honer, Meike Hutt, Simone Schmid, Jonas Zantow, Michael Hust, Stefan Dübel, Monilola A. Olayioye & Roland E. Kontermann. (2017) Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. mAbs 9:5, pages 831-843.
Read now
Read now
Cynthia Lopez-Haber, Laura Barrio-Real, Victoria Casado-Medrano & Marcelo G. Kazanietz. (2016) Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α. Molecular and Cellular Biology 36:15, pages 2011-2026.
Read now
Read now
Articles from other publishers (30)
Ruobing Leng, Yunfang Meng, Xiaomei Sun & Yingzi Zhao. (2022) NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes. Frontiers in Oncology 12.
Crossref
Crossref
Susana G Barrientos-Robledo, Jorge A Cebada-Ruiz, Juan C Rodríguez-Alba, Shantal L Baltierra-Uribe, Maria A Díaz y Orea & Héctor Romero-Ramírez. (2022) CD38 a biomarker and therapeutic target in non-hematopoietic tumors. Biomarkers in Medicine 16:5, pages 387-400.
Crossref
Crossref
Danesh Hassani, Mahmood Jeddi-Tehrani, Parisa Yousefi, Samaneh Mansouri-Fard, Maryam Mobini, Hengameh Ahmadi-Zare, Forough Golsaz-Shirazi, Mohammad Mehdi Amiri & Fazel Shokri. (2022) Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. Cancer Chemotherapy and Pharmacology 89:3, pages 347-361.
Crossref
Crossref
Farideh Ghalamfarsa, Seyyed Hossein Khatami, Omid Vakili, Mortaza Taheri-Anganeh, Amir Tajbakhsh, Amir Savardashtaki, Yousef Fazli, Leila Rezaei Uonaki, Zahra Shabaninejad, Ahmad Movahedpour & Ghasem Ghalamfarsa. (2021) Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. Immunotherapy 13:16, pages 1355-1367.
Crossref
Crossref
Limin Wu, Mohammad R Islam, Janice Lee, Hajime Takase, Shuzhen Guo, Allison M Andrews, Tetyana P Buzhdygan, Justin Mathew, Wenlu Li, Ken Arai, Eng H Lo, Servio H Ramirez & Josephine Lok. (2021) ErbB3 is a critical regulator of cytoskeletal dynamics in brain microvascular endothelial cells: Implications for vascular remodeling and blood brain barrier modulation. Journal of Cerebral Blood Flow & Metabolism 41:9, pages 2242-2255.
Crossref
Crossref
Nikola Ptáková, Petr Martínek, Luboš Holubec, Václav Janovský, Jana Vančurová, Petr Grossmann, Paloma Alcaraz Navarro, Juan F. Rodriguez Moreno, Reza Alaghehbandan, Ondřej Hes, Ondřej Májek, Miloš Pešek, Michal Michal & Ondrej Ondič. (2021)
Identification of tumors with
NRG1
rearrangement, including a novel putative pathogenic
UNC5D‐NRG1
gene fusion in prostate cancer by data‐drilling a de‐identified tumor database
. Genes, Chromosomes and Cancer 60:7, pages 474-481.
Crossref
Crossref
Douglas E. Biancur, Kevin S. Kapner, Keisuke Yamamoto, Robert S. Banh, Jasper E. Neggers, Albert S.W. Sohn, Warren Wu, Robert T. Manguso, Adam Brown, David E. Root, Andrew J. Aguirre & Alec C. Kimmelman. (2021) Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. Cell Metabolism 33:1, pages 199-210.e8.
Crossref
Crossref
Lucía Gandullo‐Sánchez, Emily Capone, Alberto Ocaña, Stefano Iacobelli, Gianluca Sala & Atanasio Pandiella. (2020) HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies. EMBO Molecular Medicine 12:5.
Crossref
Crossref
Heejin Kim, Joo Yeon Choi, Yoon Chan Rah, Jae-Cheul Ahn, Hyunchul Kim, Woo-Jin Jeong & Soon-Hyun Ahn. (2020) ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 129:4, pages 377-387.
Crossref
Crossref
Laura Bourillon, Sylvain Demontoy, Alexis Lenglet, Alexandre Zampieri, Julien Fraisse, Marta Jarlier, Florence Boissière-Michot, Hélène Perrochia, Gauthier Rathat, Véronique Garambois, Nathalie Bonnefoy, Henri-Alexandre Michaud, Thierry Chardès, Diego Tosi, André Pèlegrin, David Azria, Christel Larbouret & Céline Bourgier. (2020) Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. International Journal of Radiation Oncology*Biology*Physics 106:5, pages 1039-1051.
Crossref
Crossref
Xuemin Pan, Ping Lin, Fangyoumin Feng, Jia Li, Yuan-Yuan Li, Wentao Dai, Bo Hu, Xin-Rong Yang, Jia Fan, Hong Li & Yixue Li. (2020) Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophysics Reports 6:1, pages 19-32.
Crossref
Crossref
Nicolas Kiavue, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Celine Callens, Florence Lerebours, Jean-Yves Pierga & Francois-Clement Bidard. (2019) ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene 39:3, pages 487-502.
Crossref
Crossref
Rakesh Kumar, Bijesh George, Marcia R. Campbell, Nandini Verma, Aswathy Mary Paul, Cecília Melo-Alvim, Leonor Ribeiro, M. Radhakrishna Pillai, Luis Marques da Costa & Mark M. Moasser. 2020. Receptor Tyrosine Kinases. Receptor Tyrosine Kinases
109
160
.
C. Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A. Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S. Hoekstra, Danielle J. Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen & Sean Zhang. (2019)
Immuno-PET Imaging to Assess Target Engagement: Experience from
89
Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
. Journal of Nuclear Medicine 60:7, pages 902-909.
Crossref
Crossref
Yoram Groner, Pnina Sachs & Joseph Lotem. (2019) Leo Sachs. 14 October 1924—12 December 2013. Biographical Memoirs of Fellows of the Royal Society 66, pages 355-375.
Crossref
Crossref
Hadas Nevenzal, Meirav Noach-Hirsh, Or Skornik-Bustan, Lev Brio, Efrat Barbiro-Michaely, Yair Glick, Dorit Avrahami, Roxane Lahmi, Amit Tzur & Doron Gerber. (2019) A high-throughput integrated microfluidics method enables tyrosine autophosphorylation discovery. Communications Biology 2:1.
Crossref
Crossref
Sara S. Rinne, Charles Dahlsson Leitao, Bogdan Mitran, Tarek Z. Bass, Ken G. Andersson, Vladimir Tolmachev, Stefan Ståhl, John Löfblom & Anna Orlova. (2019) Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. Scientific Reports 9:1.
Crossref
Crossref
Rui Wang, Rajat Bhattacharya, Xiangcang Ye, Fan Fan, Delphine R. Boulbes & Lee M. Ellis. (2019) Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Molecular Cancer Research 17:1, pages 20-29.
Crossref
Crossref
Jacob P. Turowec, Esther W.T. Lau, Xiaowei Wang, Kevin R. Brown, Frederic A. Fellouse, Kamaldeep K. Jawanda, James Pan, Jason Moffat & Sachdev S. Sidhu. (2019) Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. Journal of Biological Chemistry 294:4, pages 1396-1409.
Crossref
Crossref
Ilaria Marrocco, Donatella Romaniello & Yosef Yarden. 2019. Human Monoclonal Antibodies. Human Monoclonal Antibodies
11
51
.
Satu Luhtala, Synnöve Staff, Anne Kallioniemi, Minna Tanner & Jorma Isola. (2018) Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer. BMC Cancer 18:1.
Crossref
Crossref
Donatella Romaniello, Luigi Mazzeo, Maicol Mancini, Ilaria Marrocco, Ashish Noronha, Matthew Kreitman, Swati Srivastava, Soma Ghosh, Moshit Lindzen, Tomer Meir Salame, Amir Onn, Jair Bar & Yosef Yarden. (2018) A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research 24:22, pages 5610-5621.
Crossref
Crossref
Emily Capone, Alessia Lamolinara, Daniela D'Agostino, Cosmo Rossi, Vincenzo De Laurenzi, Manuela Iezzi, Stefano Iacobelli & Gianluca Sala. (2018) EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Journal of Controlled Release 277, pages 48-56.
Crossref
Crossref
Rafał Kampa, Ilona Bednarek & Daniel Sypniewski. (2018) Monoclonal antibodies in regulation of signal transduction
of Epidermal Growth Factor Receptor (EGFR) pathway in cancer cells. Annales Academiae Medicae Silesiensis 72, pages 12-20.
Crossref
Crossref
Emily Capone, Francesco Giansanti, Sara Ponziani, Alessia Lamolinara, Manuela Iezzi, Annamaria Cimini, Francesco Angelucci, Rossana La Sorda, Vincenzo De Laurenzi, Pier Giorgio Natali, Rodolfo Ippoliti, Stefano Iacobelli & Gianluca Sala. (2017) EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. Oncotarget 8:56, pages 95412-95424.
Crossref
Crossref
Christophe Le Clorennec, Hervé Bazin, Olivier Dubreuil, Christel Larbouret, Charline Ogier, Yassamine Lazrek, Véronique Garambois, Marie-Alix Poul, Philippe Mondon, Jean-Marc Barret, Gérard Mathis, Jean-François Prost, André Pèlegrin & Thierry Chardès. (2017) Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3. Molecular Cancer Therapeutics 16:7, pages 1312-1323.
Crossref
Crossref
Bhumika Wadhwa, Ubaid Makhdoomi, Ram Vishwakarma & Fayaz Malik. (2017) Protein kinase B. Anti-Cancer Drugs 28:6, pages 569-580.
Crossref
Crossref
Sean P. Kennedy, Jordan F. Hastings, Jeremy Z. R. Han & David R. Croucher. (2016) The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. Frontiers in Cell and Developmental Biology 4.
Crossref
Crossref
Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie-Alix Poul, Philippe Mondon, Gerry Melino, André Pèlegrin & Thierry Chardès. (2016) The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget 7:24, pages 37013-37029.
Crossref
Crossref
H M Tang, K T Kuay, P F Koh, M Asad, T Z Tan, V Y Chung, S C Lee, J P Thiery & RY-J Huang. (2016) An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discovery 2:1.
Crossref
Crossref